Sir,

*Cupriavidus* are Gram-negative non-lactose-fermenting motile bacilli with peritrichous flagella, a number of which were previously and successively classified in the *Ralstonia* and *Wautersia* genera. Until the recent expansion of MALDI-TOF MS, *Cupriavidus* could be mistaken for *Burkholderia* or *Pseudomonas* species. They are resistant to heavy metals and have been described from environmental (soil and water) samples, as well as from human samples.[@dkaa066-B1]*Cupriavidus gilardii*, *Cupriavidus pauculus* and *Cupriavidus metallidurans* are involved in invasive human infections, such as bacteraemia and pneumonia, most of which (though not exclusively) occur in immunocompromised patients.[@dkaa066-B2] Additionally, *Cupriavidus* species, *Cupriavidus respiraculi* in particular, are increasingly identified in patients with cystic fibrosis (CF).[@dkaa066-B5] However, their clinical relevance in CF is not established. Due to the rare occurrence of *Cupriavidus* infections, antibiotic susceptibility data are only available from sparse case reports. Therefore, we determined the MICs of 20 antibiotics for a panel of *Cupriavidus* clinical strains, mainly from respiratory samples of CF patients (82%).

Thirty-seven epidemiologically unrelated clinical isolates of *Cupriavidus* obtained from the collection of the French Observatoire *Burkholderia cepacia* and from 11 French hospitals, as well as two type strains from clinical sources, i.e. *C. pauculus* LMG 3244^T^ and *C. respiraculi* LMG 21510^T^ (Laboratory of Microbiology, Ghent University, Ghent, Belgium),[@dkaa066-B1] were included. Isolates were identified by amplified ribosomal DNA restriction analysis (ARDRA)[@dkaa066-B6] and MALDI-TOF MS (Maldi Biotyper Microflex^®^, Bruker Daltonics, Bremen, Germany; IVD 7712). The experimental panel thus comprised 18 *C. respiraculi*, 6 *C. gilardii*, 5 *C. pauculus*, 4 *C. metallidurans*, 2 *Cupriavidus necator*, 2 *Cupriavidus taiwanensis*, 1 *Cupriavidus basilensis* and 1 unidentified *Cupriavidus* sp.

The MICs of 20 antibiotics, listed in Table [1](#dkaa066-T1){ref-type="table"}, were determined using the broth microdilution method, as recommended by EUCAST ([www.eucast.org](http://www.eucast.org)). Briefly, each strain was inoculated on a blood agar plate (bioMérieux, Marcy-l'Étoile, France) for 16 h at 35°C. Bacterial suspensions in Mueller--Hinton broth (Bio-Rad, Marnes-la-Coquette, France) at concentrations of 5 × 10^5^ cfu/mL were dispensed in 96-well microtitre plates (Dutscher, Brumath, France, 160 μL per well). Antimicrobial agents were added at increasing 2-fold concentrations (40 μL per well). The MICs were determined as the lowest antibiotic concentrations that inhibited visible bacterial growth after an 18 ± 2 h incubation at 35°C in an aerobic atmosphere. *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853 and *Staphylococcus aureus* ATCC 29213 were used as controls. All MICs were determined in triplicate and replicates never differed by more than 2-fold. For each MIC determination, the median of the replicates was recorded as the MIC. The MICs were interpreted according to *Pseudomonas* EUCAST breakpoints (2019) for colistin, amikacin and tobramycin, according to non-Enterobacteriaceae CLSI breakpoints (2019; <https://clsi.org>) for minocycline and co-trimoxazole and according to pharmacokinetic/pharmacodynamic (non-species-related) EUCAST breakpoints (2019) for the other antibiotics, except for temocillin, for which the previously proposed breakpoint of 16 mg/L was used.[@dkaa066-B7] The EUCAST and CLSI breakpoints that could be used to interpret *Cupriavidus* MICs are listed in Table [S1](#sup1){ref-type="supplementary-material"} (available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *JAC* Online).

###### 

MICs of 20 antibiotics for 39 *Cupriavidus* clinical strains, including two type strains, determined by the broth microdilution method

  Bacteria (*n*)                                                                           Antibiotic   MIC (mg/L)   Percentage susceptible (breakpoint, mg/L)  Percentage resistant (breakpoint, mg/L)   
  --------------------------------------------------------------------------------------- ------------ ------------ ------------------------------------------- ----------------------------------------- ------------
  *Cupriavidus* spp., all isolates (39)                                                     amikacin        64                          512                     23 (≤8)                                   72 (\>16)
  amoxicillin                                                                                 512         \>512                       5 (≤2)                    90 (\>8)                                  
  amoxicillin/clavulanate                                                                     256         \>512                       8 (≤2)                    87 (\>8)                                  
  aztreonam                                                                                    32          256                        0 (≤4)                    97 (\>8)                                  
  cefepime                                                                                     1            4                         95 (≤4)                   0 (\>8)                                   
  cefotaxime                                                                                   1            2                         82 (≤1)                   8 (\>2)                                   
  ceftazidime                                                                                  16           32                        23 (≤4)                   54 (\>8)                                  
  ceftazidime/avibactam                                                                        8            32                        69 (≤8)                   31 (\>8)                                  
  ceftolozane/tazobactam                                                                       2            8                         90 (≤4)                   10 (\>4)                                  
  ceftriaxone                                                                                  1            4                         74 (≤1)                   10 (\>2)                                  
  ciprofloxacin                                                                              0.125          1                       74 (≤0.25)                  18 (\>0.5)                                
  colistin                                                                                     2            16                        56 (≤2)                   44 (\>2)                                  
  co-trimoxazole                                                                               1           128                        62 (≤2)                   38 (\>2)                                  
  imipenem                                                                                     2            8                         69 (≤2)                   21 (\>4)                                  
  levofloxacin                                                                                0.25          2                        79 (≤0.5)                  18 (\>1)                                  
  meropenem                                                                                    32           64                        8 (≤2)                    74 (\>8)                                  
  minocycline                                                                                ≤0.06         0.5                       100 (≤4)                   0 (\>8)                                   
  piperacillin/tazobactam                                                                      8           128                        46 (≤4)                   26 (\>16)                                 
  temocillin                                                                                   32          512                       31 (≤16)                   69 (\>16)                                 
  tobramycin                                                                                  256         \>256                       21 (≤4)                   79 (\>4)                                  
  *C. respiraculi* (18)                                                                     amikacin       128                          512                     6 (≤8)                                    89 (\>16)
  amoxicillin                                                                                 512         \>512                       0 (≤2)                    100 (\>8)                                 
  amoxicillin/clavulanate                                                                     512         \>512                       0 (≤2)                    100 (\>8)                                 
  aztreonam                                                                                    32           32                        0 (≤4)                    100 (\>8)                                 
  cefepime                                                                                     2            4                         89 (≤4)                   0 (\>8)                                   
  cefotaxime                                                                                   1            2                         78 (≤1)                   11 (\>2)                                  
  ceftazidime                                                                                  16           16                        6 (≤4)                    61 (\>8)                                  
  ceftazidime/avibactam                                                                        8            16                        72 (≤8)                   28 (\>8)                                  
  ceftolozane/tazobactam                                                                       2            4                         94 (≤4)                   6 (\>4)                                   
  ceftriaxone                                                                                  1            4                         67 (≤1)                   17 (\>2)                                  
  ciprofloxacin                                                                               0.06         \>16                     83 (≤0.25)                  17 (\>0.5)                                
  colistin                                                                                     1            2                         94 (≤2)                   6 (\>2)                                   
  co-trimoxazole                                                                              0.5          128                        78 (≤2)                   22 (\>2)                                  
  imipenem                                                                                     2            8                         61 (≤2)                   22 (\>4)                                  
  levofloxacin                                                                               0.125          16                       83 (≤0.5)                  17 (\>1)                                  
  meropenem                                                                                    64           64                        0 (≤2)                    83 (\>8)                                  
  minocycline                                                                                ≤0.06        0.125                      100 (≤4)                   0 (\>8)                                   
  piperacillin/tazobactam                                                                      8            16                        39 (≤4)                   11 (\>16)                                 
  temocillin                                                                                   32           32                       50 (≤16)                   50 (\>16)                                 
  tobramycin                                                                                 \>256        \>256                       6 (≤4)                    94 (\>4)                                  
  *C. pauculus* (5) and *C. metallidurans* (4)                                              amikacin        8                           128                     56 (≤8)                                   33 (\>16)
  amoxicillin                                                                                 256          512                        0 (≤2)                    78 (\>8)                                  
  amoxicillin/clavulanate                                                                     128          256                        11 (≤2)                   78 (\>8)                                  
  aztreonam                                                                                   256          512                        0 (≤4)                    100 (\>8)                                 
  cefepime                                                                                    0.5           1                        100 (≤4)                   0 (\>8)                                   
  cefotaxime                                                                                   1            2                         67 (≤1)                   11 (\>2)                                  
  ceftazidime                                                                                  8            16                        33 (≤4)                   44 (\>8)                                  
  ceftazidime/avibactam                                                                        8            16                        78 (≤8)                   22 (\>8)                                  
  ceftolozane/tazobactam                                                                       2            4                        100 (≤4)                   0 (\>4)                                   
  ceftriaxone                                                                                  1            2                         78 (≤1)                   0 (\>2)                                   
  ciprofloxacin                                                                               0.5           1                       44 (≤0.25)                  44 (\>0.5)                                
  colistin                                                                                     16           32                        0 (≤2)                    100 (\>2)                                 
  co-trimoxazole                                                                               16          256                        22 (≤2)                   78 (\>2)                                  
  imipenem                                                                                    0.25          2                        100 (≤2)                   0 (\>4)                                   
  levofloxacin                                                                                 1            2                        44 (≤0.5)                  44 (\>1)                                  
  meropenem                                                                                    16           64                        11 (≤2)                   67 (\>8)                                  
  minocycline                                                                                 0.25         0.5                       100 (≤4)                   0 (\>8)                                   
  piperacillin/tazobactam                                                                      2            32                        67 (≤4)                   22 (\>16)                                 
  temocillin                                                                                  256          512                        0 (≤16)                   100 (\>16)                                
  tobramycin                                                                                   64          128                        44 (≤4)                   56 (\>4)                                  
  *C. gilardii* (6)                                                                         amikacin        64                          128                     0 (≤8)                                    100 (\>16)
  amoxicillin                                                                                \>512        \>512                       0 (≤2)                    100 (\>8)                                 
  amoxicillin/clavulanate                                                                    \>512        \>512                       0 (≤2)                    100 (\>8)                                 
  aztreonam                                                                                   128          128                        0 (≤4)                    100 (\>8)                                 
  cefepime                                                                                     4            4                        100 (≤4)                   0 (\>8)                                   
  cefotaxime                                                                                   1            1                        100 (≤1)                   0 (\>2)                                   
  ceftazidime                                                                                  32           32                        17 (≤4)                   83 (\>8)                                  
  ceftazidime/avibactam                                                                        32           32                        33 (≤8)                   67 (\>8)                                  
  ceftolozane/tazobactam                                                                       8            16                        50 (≤4)                   50 (\>4)                                  
  ceftriaxone                                                                                  1            2                         67 (≤1)                   17 (\>2)                                  
  ciprofloxacin                                                                               0.25         0.25                     83 (≤0.25)                  0 (\>0.5)                                 
  colistin                                                                                     1            4                         67 (≤2)                   33 (\>2)                                  
  co-trimoxazole                                                                               1            1                         83 (≤2)                   17 (\>2)                                  
  imipenem                                                                                     8            8                         17 (≤2)                   67 (\>4)                                  
  levofloxacin                                                                                0.25         0.25                     100 (≤0.5)                  0 (\>1)                                   
  meropenem                                                                                    64           64                        0 (≤2)                    100 (\>8)                                 
  minocycline                                                                                0.125        0.125                      100 (≤4)                   0 (\>8)                                   
  piperacillin/tazobactam                                                                     128          128                        0 (≤4)                    83 (\>16)                                 
  temocillin                                                                                  512         \>512                       0 (≤16)                   100 (\>16)                                
  tobramycin                                                                                  256         \>256                       0 (≤4)                    100 (\>4)                                 
  *C. basilensis* (1), *C. necator* (2), *C. taiwanensis* (2) and *Cupriavidus* sp. (1)     amikacin        32                          64                      50 (≤8)                                   50 (\>16)
  amoxicillin                                                                                  32          256                        33 (≤2)                   67 (\>8)                                  
  amoxicillin/clavulanate                                                                      16           64                        33 (≤2)                   50 (\>8)                                  
  aztreonam                                                                                    64          128                        0 (≤4)                    83 (\>8)                                  
  cefepime                                                                                   ≤0.25        ≤0.25                      100 (≤4)                   0 (\>8)                                   
  cefotaxime                                                                                  0.5           1                        100 (≤1)                   0 (\>2)                                   
  ceftazidime                                                                                  4            8                         67 (≤4)                   17 (\>8)                                  
  ceftazidime/avibactam                                                                        4            8                         83 (≤8)                   17 (\>8)                                  
  ceftolozane/tazobactam                                                                       1            1                        100 (≤4)                   0 (\>4)                                   
  ceftriaxone                                                                                 0.25          1                        100 (≤1)                   0 (\>2)                                   
  ciprofloxacin                                                                              0.125         0.25                     83 (≤0.25)                  0 (\>0.5)                                 
  colistin                                                                                     16           16                        17 (≤2)                   83 (\>2)                                  
  co-trimoxazole                                                                               16           64                        50 (≤2)                   50 (\>2)                                  
  imipenem                                                                                    0.25          2                        100 (≤2)                   0 (\>4)                                   
  levofloxacin                                                                               0.125         0.25                     100 (≤0.5)                  0 (\>1)                                   
  meropenem                                                                                    8            16                        33 (≤2)                   33 (\>8)                                  
  minocycline                                                                                ≤0.06         0.5                       100 (≤4)                   0 (\>8)                                   
  piperacillin/tazobactam                                                                      1            4                         83 (≤4)                   17 (\>16)                                 
  temocillin                                                                                  128          512                       50 (≤16)                   50 (\>16)                                 
  tobramycin                                                                                   64           64                        50 (≤4)                   50 (\>4)                                  

The susceptibility testing results are summarized in Table [1](#dkaa066-T1){ref-type="table"} and the full MIC distributions of each tested antibiotic are available in Figure [S1](#sup1){ref-type="supplementary-material"}. Since *C. pauculus* and *C. metallidurans* are phylogenetically close species[@dkaa066-B1] and exhibited the same susceptibility profiles, they were considered as a group. Our collection comprises very few strains of *C. basilensis, C. necator, C. taiwanensis and Cupriavidus sp*. (maximum *n*=2 for each species). Moreover, these species have similar antibiotic susceptibility profiles, that\'s why they were also considered as a group. The susceptibility testing results interpreted with CLSI breakpoints are available in Table [S2](#sup1){ref-type="supplementary-material"}. The only significant change in our study between the EUCAST and CLSI interpretations concerned piperacillin/tazobactam. Eleven strains had an MIC of 8 or 16 mg/L (nine *C. respiraculi*). They were classified as susceptible to piperacillin/tazobactam according to CLSI breakpoints, but intermediate according to EUCAST breakpoints.

Nearly all strains were resistant to amoxicillin, amoxicillin/clavulanate, temocillin and aztreonam. Regarding cephalosporins, only 23% of *Cupriavidus* strains were ceftazidime susceptible, whereas 74% and 82% were susceptible to ceftriaxone or cefotaxime, respectively. The ceftolozane/tazobactam combination also demonstrated good activity, except against *C. gilardii.* For most strains, ceftazidime/avibactam MICs were similar compared with ceftazidime alone. Cefepime was the most active β-lactam, with 95% of strains being susceptible, whereas only a few strains were susceptible to meropenem (8%). Interspecies differences were observed for piperacillin/tazobactam and imipenem, since they were less active against *C. respiraculi* and *C. gilardii* than against the other species. Such discrepancies between meropenem and imipenem activities were previously noticed in case reports.[@dkaa066-B2]^,^[@dkaa066-B3] Similarly to *P. aeruginosa*, they could be due to the overexpression of efflux pumps from the resistance-nodulation-division family.[@dkaa066-B8] Indeed, a homologue of the MexAB OprM efflux pump that extrudes meropenem in *P. aeruginosa* has been identified in *C. gilardii*.[@dkaa066-B9]

Aminoglycosides were poorly active, in agreement with case reports,[@dkaa066-B2]^,^[@dkaa066-B3] probably due to efflux pumps and aminoglycoside-modifying enzymes.[@dkaa066-B9] Minocycline was the most active antibiotic, with very low MICs and a 100% susceptibility rate. Fluoroquinolones were frequently active, with over 80% of strains being susceptible, except for *C. pauculus* *and C.* *metallidurans.* Interspecies discrepancies were also noticed for co-trimoxazole. It was active against approximatively 80% of *C. gilardii* and *C. respiraculi* strains, whereas more than 50% of the strains belonging to other species were resistant.

Over 90% of *C. respiraculi* and 67% of *C. gilardii* strains were susceptible to colistin, while strains from the other species were mostly colistin-resistant. Colistin susceptibility was one of the characteristics of the *Cupriavidus* genus initially described by Vaneechoutte *et al*.[@dkaa066-B1] However, Petrou *et al*.[@dkaa066-B10] showed that the expression of ArnT was particularly strong in a strain of *C. metallidurans.* This enzyme catalyses the attachment of the cationic sugar 4-amino-4-deoxy [l]{.smallcaps}-arabinose ([l]{.smallcaps}-Ara4N) to lipid A phosphate groups. The subsequent reduction of negative membrane charge is responsible for colistin resistance. We detected homologues of *arnT* (CP000353.2: 1481129--1482725) using BLASTn in *C. basilensis*, *C. necator*, *C. pauculus* and *C. taiwanensis* sequenced strains (a query cover \>80%, an identity \>70% and an E value \<1 × 10^−40^ were chosen as cut-off values for significance), which is in accordance with the high rate of colistin resistance in these species observed in our study. Additionally, *C. gilardii* appears to be the origin of the gene *mcr-5*, which is an emerging plasmid-mediated mechanism of colistin resistance in other environmental species such as *Salmonella* and *Pseudomonas.*[@dkaa066-B11]

In conclusion, our study showed that minocycline and cefepime exhibited the best *in vitro* activities against *Cupriavidus* strains. Meropenem, aminoglycosides and polymyxins, often considered antibiotics of last resort against infections caused by Gram-negative bacilli, do not have reliable activity against *Cupriavidus*. Perhaps resistance to these agents confers a selective advantage to *Cupriavidus* and therefore it may emerge in clinical scenarios where these agents are used, such as in patients with CF. Imipenem was more active than meropenem and cefotaxime/ceftriaxone was more active than ceftazidime. Ceftolozane/tazobactam had reasonable activity against *Cupriavidus*, whereas the novel inhibitor avibactam does not seem to add to the activity of ceftazidime. Interspecies variations were observed, especially concerning colistin, co-trimoxazole, fluoroquinolones and piperacillin/tazobactam. Clinical data is now required to establish the optimal treatment of *Cupriavidus* infections.
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